|
Product event summary: the afr-00001 affera¿ sphere-9¿ catheter with lot 0233235815 and data files were returned and analyzed.The log files were analyzed, and timestamps/errors were observed with catheter serial number (b)(6).During external visual inspection, the catheter was found to be intact, and no defects were observed.The cirris tester was used on the catheter for shorts and mapping tests, and the tests passed successfully.The catheter was functionally tested using test capital equipment.Radiofrequency (rf) and pulse field ablations were completed successfully with the catheter.A new map was started, and the catheter was able to map appropriately.In conclusion, the reported clinical issues cannot be assessed through data analysis.The catheter passed the returned product inspection per specification.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
It was reported that an affera mapping system with a sphere 9 catheter was used during a ventricular tachycardia ablation, two ventricular tachycardia morphologies were induced with suspected origin from the inferior septum of the left ventricle, and premature ventricular contractions were described as a suspected trigger for ventricular tachycardia or ventricular fibrillation.A scar map was created during right ventricular lead pacing and left ventricular scar homogenization was performed on the inferior and septal walls, including lesion delivery at the inferior basal septum and at the left posterior fascicle based on mapped signals including purkinje potentials.Pulsed field ablation and radiofrequency ablation lesions were delivered, and complete type 3 heart block was later recognized after ablation performed under left ventricular pacing, with a concern that the posterior fascicle may have been the only remaining conduction pathway.The procedure was aborted while the patient was under general anesthesia after recognition of complete heart block, and another manufacturer's biventricular implantable cardioverter defibrillator was implanted.No further patient complications have been reported as a result of this event.
|